UBS Group’s Kalaris Therapeutics, Inc. Common Stock KLRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $11K | Sell |
4,116
-5,145
| -56% | -$13.7K | ﹤0.01% | 7488 |
|
|
2025
Q1 | $74.4K | Buy |
9,261
+3,804
| +70% | +$30.5K | ﹤0.01% | 5999 |
|
|
2024
Q4 | $52.7K | Buy |
5,457
+5,360
| +5,526% | +$51.8K | ﹤0.01% | 6043 |
|
|
2024
Q3 | $1.8K | Sell |
97
-1,524
| -94% | -$28.2K | ﹤0.01% | 7334 |
|
|
2024
Q2 | $27K | Sell |
1,621
-792
| -33% | -$13.2K | ﹤0.01% | 5969 |
|
|
2024
Q1 | $41.9K | Sell |
2,413
-223
| -8% | -$3.87K | ﹤0.01% | 5425 |
|
|
2023
Q4 | $41.2K | Buy |
2,636
+1,060
| +67% | +$16.6K | ﹤0.01% | 5454 |
|
|
2023
Q3 | $78K | Buy |
1,576
+1,223
| +346% | +$60.5K | ﹤0.01% | 4879 |
|
|
2023
Q2 | $27.6K | Sell |
353
-349
| -50% | -$27.3K | ﹤0.01% | 5678 |
|
|
2023
Q1 | $63.6K | Sell |
702
-121
| -15% | -$11K | ﹤0.01% | 5192 |
|
|
2022
Q4 | $97.1K | Buy |
823
+787
| +2,186% | +$92.9K | ﹤0.01% | 5008 |
|
|
2022
Q3 | $6K | Sell |
36
-9
| -20% | -$1.5K | ﹤0.01% | 7980 |
|
|
2022
Q2 | $4K | Hold |
45
| – | – | ﹤0.01% | 8115 |
|
|
2022
Q1 | $7K | Sell |
45
-2,733
| -98% | -$425K | ﹤0.01% | 7800 |
|
|
2021
Q4 | $827K | Buy |
2,778
+863
| +45% | +$257K | ﹤0.01% | 3581 |
|
|
2021
Q3 | $1.1M | Buy |
1,915
+1,129
| +144% | +$651K | ﹤0.01% | 3186 |
|
|
2021
Q2 | $357K | Sell |
786
-2,337
| -75% | -$1.06M | ﹤0.01% | 3968 |
|
|
2021
Q1 | $1.68M | Buy |
3,123
+3,111
| +25,925% | +$1.67M | ﹤0.01% | 2922 |
|
|
2020
Q4 | $11K | Sell |
12
-32
| -73% | -$29.3K | ﹤0.01% | 6412 |
|
|
2020
Q3 | $28K | Buy |
+44
| New | +$28K | ﹤0.01% | 5192 |
|